• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PTX
Click for more information
0.00% 4.0¢

PRESCIENT THERAPEUTICS LIMITED - Announcements

Market Cap $32.21M  ! watchlist Created with Sketch. Add to my watchlist

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The... Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PTX Phase 1b/2 Ovarian Trial Commences 2nd Dose EscalationPRICE SENSITIVE08/12/16
PTX Results of Annual General Meeting30/11/16
PTX Change of Director's Interest Notice09/11/16
PTX Receipt of R&D Tax Rebate-PTX.AX PRICE SENSITIVE02/11/16
PTX Notice of Annual General Meeting/Proxy Form-PTX.AX 28/10/16
PTX September 2016 Appendix 4C - Quarterly-PTX.AX PRICE SENSITIVE28/10/16
PTX Response to ASX Price Query-PTX.AX PRICE SENSITIVE19/10/16
PTX First patient at Moffitt dosed in Phase 1b/2 breast trial-PTX.AX PRICE SENSITIVE26/09/16
PTX Rodman & Renshaw Global Investment conference Presentation-PTX.AX 13/09/16
PTX PTX presents at Rodman & Renshaw Investment conference-PTX.AX 13/09/16
PTX Appendix 3B-PTX.AX 12/09/16
PTX Appendix 4G and Corporate Governance Statement-PTX.AX 31/08/16
PTX Appendix 4E and 2016 Annual Report-PTX.AX PRICE SENSITIVE31/08/16
PTX Section 708A Cleansing Notice and Appendix 3B-PTX.AX 16/08/16
PTX USPTO Grants Allowances for Two PTX-200 Patents-PTX.AX PRICE SENSITIVE04/08/16
PTX Change of Director's Interest Notice-PTX.AX 27/07/16
PTX Change to exercise price of options-PTX.AX PRICE SENSITIVE20/07/16
PTX Change in substantial holding-PTX.AX 20/07/16
PTX Amended Share Trading Policy-PTX.AX 20/07/16
PTX June 2016 Appendix 4C - Quarterly-PTX.AX PRICE SENSITIVE20/07/16
PTX Section 708A Cleansing Notice and Appendix 3B-PTX.AX 18/07/16
PTX Shortfall Placement Oversubscribed-PTX.AX 12/07/16
PTX Change in substantial holding for PTX,PTX-AEF.AX 07/07/16
PTX Change in substantial holding for PTX,PTX-AEF.AX 07/07/16
PTX Change in substantial holding-PTX.AX 05/07/16
PTX Ceasing to be a substantial holder-PTX.AX 01/07/16
PTX Change of Director's Interest Notices x2-PTX.AX 01/07/16
PTX Completion of Entitlement Issue Allotment and Appendix 3B-PTX.AX 30/06/16
PTX Entitlement Offer Closure and Shortfall Notification-PTX.AX 29/06/16
PTX Becoming a substantial holder from AEF,AEF-PTX.AX 28/06/16
PTX Becoming a substantial holder from AEF,AEF-PTX.AX 28/06/16
PTX Becoming a substantial holder-PTX.AX 24/06/16
PTX Change in substantial holding-PTX.AX 24/06/16
PTX Change in substantial holding-PTX.AX 24/06/16
PTX Tranche 2 Capital Raising Complete and Appendix 3B-PTX.AX 23/06/16
PTX Tranche 2 Capital Raising Complete and Appendix 3B-PTX.AX 23/06/16
PTX Results of Meeting-PTX.AX 22/06/16
PTX Extension of Closing Date of Entitlement Offer-PTX.AX 16/06/16
PTX Yale Joins PTX's Phase 1b/2 AML Clinical Trial-PTX.AX PRICE SENSITIVE15/06/16
PTX Despatch of Pro-rata Rights Issue Offer Documents-PTX.AX 06/06/16
PTX Replacement Entitlement Offer Prospectus-PTX.AX PRICE SENSITIVE03/06/16
PTX Rights Issue Update-PTX.AX 01/06/16
PTX Change in substantial holding-PTX.AX 26/05/16
PTX Tranche 1 Capital Raising Complete and Appendix 3B-PTX.AX 24/05/16
PTX Notice of General Meeting/Proxy Form-PTX.AX 23/05/16
PTX Letter to Optionholders-PTX.AX 18/05/16
PTX Letter to Ineligible shareholders-PTX.AX 18/05/16
PTX Letter to Eligible Shareholders-PTX.AX 18/05/16
PTX Appendix 3B-PTX.AX 18/05/16
PTX Offer Document-PTX.AX PRICE SENSITIVE18/05/16
PTX PTX Secures $7.0M Capital Raising-PTX.AX PRICE SENSITIVE18/05/16
PTX Trading Halt-PTX.AX PRICE SENSITIVE16/05/16
PTX March 2016 Appendix 4C - Quarterly-PTX.AX PRICE SENSITIVE21/04/16
PTX Investor Presentation - April 2016-PTX.AX 13/04/16
PTX RedChip Issues Research on Prescient Therapeutics31/03/16
PTX Edison Investment Research Initiates Coverage03/03/16
PTX PTX Featured on Bloomberg's - The Redchip Money Report02/03/16
PTX Appendix 4D and Half Year Financial Report17/02/16
PTX PTX-200 Breast Cancer Trial ProgressesPRICE SENSITIVE17/02/16
PTX Steven Yatomi-Clarke Appointed CEOPRICE SENSITIVE15/02/16
PTX Appendix 3B05/02/16
PTX December 2015 Appendix 4C - QuarterlyPRICE SENSITIVE25/01/16
PTX PTX Presents at NobleCon1221/01/16
PTX Response to ASX Price QueryPRICE SENSITIVE19/01/16
PTX Yale Hematolgy Leader Joins PTX Scientific Advisory Board14/01/16
PTX PTX to present at Biotech Showcase 2016 in San Francisco11/01/16
PTX FDA Allows PTX IND for Leukemia Phase Ib & II TrialsPRICE SENSITIVE08/01/16
PTX Appendix 3B - Release of securities from escrow11/12/15
PTX Change of Director's Interest Notice08/12/15
PTX Becoming a substantial holder03/12/15
PTX Change in substantial holding01/12/15
PTX Investor Presentation - December 201501/12/15
PTX Section 708A Cleansing Notice and Appendix 3B30/11/15
PTX H. Lee Moffitt Cancer Center Leukaemia Oncologist Joins SAB30/11/15
PTX MD Anderson Leukaemia Expert Joins PTX SAB26/11/15
PTX Change in substantial holding25/11/15
PTX Change of Director's Interest Notice x425/11/15
PTX Additional Placement Raises $1.0 millionPRICE SENSITIVE25/11/15
PTX Share Purchase Plan Completion & Appendix 3B23/11/15
PTX Release of Securities from Escrow20/11/15
PTX Share Purchase Plan Results18/11/15
PTX PTX Shareholder Newsletter09/11/15
PTX Results of Meeting04/11/15
PTX New Investor Presentation04/11/15
PTX Share Purchase Plan - Documentation issued to shareholders02/11/15
PTX September 2015 Appendix 4C - QuarterlyPRICE SENSITIVE30/10/15
PTX Cleansing Notice - Share Purchase Plan29/10/15
PTX Share Purchase Plan Offer Document29/10/15
PTX SPP Fully Underwritten up to target amount of $1.03 millionPRICE SENSITIVE29/10/15
PTX Trading HaltPRICE SENSITIVE28/10/15
PTX Final Director's Interest Notice15/10/15
PTX Executive Management ChangePRICE SENSITIVE15/10/15
PTX Notice of Annual General Meeting/Proxy Form05/10/15
PTX CSO named among Top 20 Translational Researchers by Nature01/09/15
PTX Two new Patents granted to Protect Lead Asset PTX-200PRICE SENSITIVE31/08/15
PTX 2015 Corporate Governance Statement and Appendix 4G28/08/15
PTX Prescient Appendix 4E and 2015 Annual ReportPRICE SENSITIVE28/08/15
PTX PTX-200 Phase 1B/2 Clinical Trial UpdatePRICE SENSITIVE26/08/15
PTX Proposed Grant of Options to Non-Executive DirectorsPRICE SENSITIVE21/08/15
PTX Prescient Shareholder Newsletter12/08/15
PTX Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation
08/12/16PRICE SENSITIVE
PTX Results of Annual General Meeting
30/11/16
PTX Change of Director's Interest Notice
09/11/16
PTX Receipt of R&D Tax Rebate-PTX.AX
02/11/16PRICE SENSITIVE
PTX Notice of Annual General Meeting/Proxy Form-PTX.AX
28/10/16
PTX September 2016 Appendix 4C - Quarterly-PTX.AX
28/10/16PRICE SENSITIVE
PTX Response to ASX Price Query-PTX.AX
19/10/16PRICE SENSITIVE
PTX First patient at Moffitt dosed in Phase 1b/2 breast trial-PTX.AX
26/09/16PRICE SENSITIVE
PTX Rodman & Renshaw Global Investment conference Presentation-PTX.AX
13/09/16
PTX PTX presents at Rodman & Renshaw Investment conference-PTX.AX
13/09/16
PTX Appendix 3B-PTX.AX
12/09/16
PTX Appendix 4G and Corporate Governance Statement-PTX.AX
31/08/16
PTX Appendix 4E and 2016 Annual Report-PTX.AX
31/08/16PRICE SENSITIVE
PTX Section 708A Cleansing Notice and Appendix 3B-PTX.AX
16/08/16
PTX USPTO Grants Allowances for Two PTX-200 Patents-PTX.AX
04/08/16PRICE SENSITIVE
PTX Change of Director's Interest Notice-PTX.AX
27/07/16
PTX Change to exercise price of options-PTX.AX
20/07/16PRICE SENSITIVE
PTX Change in substantial holding-PTX.AX
20/07/16
PTX Amended Share Trading Policy-PTX.AX
20/07/16
PTX June 2016 Appendix 4C - Quarterly-PTX.AX
20/07/16PRICE SENSITIVE
PTX Section 708A Cleansing Notice and Appendix 3B-PTX.AX
18/07/16
PTX Shortfall Placement Oversubscribed-PTX.AX
12/07/16
PTX Change in substantial holding for PTX,PTX-AEF.AX
07/07/16
PTX Change in substantial holding for PTX,PTX-AEF.AX
07/07/16
PTX Change in substantial holding-PTX.AX
05/07/16
PTX Ceasing to be a substantial holder-PTX.AX
01/07/16
PTX Change of Director's Interest Notices x2-PTX.AX
01/07/16
PTX Completion of Entitlement Issue Allotment and Appendix 3B-PTX.AX
30/06/16
PTX Entitlement Offer Closure and Shortfall Notification-PTX.AX
29/06/16
PTX Becoming a substantial holder from AEF,AEF-PTX.AX
28/06/16
PTX Becoming a substantial holder from AEF,AEF-PTX.AX
28/06/16
PTX Becoming a substantial holder-PTX.AX
24/06/16
PTX Change in substantial holding-PTX.AX
24/06/16
PTX Change in substantial holding-PTX.AX
24/06/16
PTX Tranche 2 Capital Raising Complete and Appendix 3B-PTX.AX
23/06/16
PTX Tranche 2 Capital Raising Complete and Appendix 3B-PTX.AX
23/06/16
PTX Results of Meeting-PTX.AX
22/06/16
PTX Extension of Closing Date of Entitlement Offer-PTX.AX
16/06/16
PTX Yale Joins PTX's Phase 1b/2 AML Clinical Trial-PTX.AX
15/06/16PRICE SENSITIVE
PTX Despatch of Pro-rata Rights Issue Offer Documents-PTX.AX
06/06/16
PTX Replacement Entitlement Offer Prospectus-PTX.AX
03/06/16PRICE SENSITIVE
PTX Rights Issue Update-PTX.AX
01/06/16
PTX Change in substantial holding-PTX.AX
26/05/16
PTX Tranche 1 Capital Raising Complete and Appendix 3B-PTX.AX
24/05/16
PTX Notice of General Meeting/Proxy Form-PTX.AX
23/05/16
PTX Letter to Optionholders-PTX.AX
18/05/16
PTX Letter to Ineligible shareholders-PTX.AX
18/05/16
PTX Letter to Eligible Shareholders-PTX.AX
18/05/16
PTX Appendix 3B-PTX.AX
18/05/16
PTX Offer Document-PTX.AX
18/05/16PRICE SENSITIVE
PTX PTX Secures $7.0M Capital Raising-PTX.AX
18/05/16PRICE SENSITIVE
PTX Trading Halt-PTX.AX
16/05/16PRICE SENSITIVE
PTX March 2016 Appendix 4C - Quarterly-PTX.AX
21/04/16PRICE SENSITIVE
PTX Investor Presentation - April 2016-PTX.AX
13/04/16
PTX RedChip Issues Research on Prescient Therapeutics
31/03/16
PTX Edison Investment Research Initiates Coverage
03/03/16
PTX PTX Featured on Bloomberg's - The Redchip Money Report
02/03/16
PTX Appendix 4D and Half Year Financial Report
17/02/16
PTX PTX-200 Breast Cancer Trial Progresses
17/02/16PRICE SENSITIVE
PTX Steven Yatomi-Clarke Appointed CEO
15/02/16PRICE SENSITIVE
PTX Appendix 3B
05/02/16
PTX December 2015 Appendix 4C - Quarterly
25/01/16PRICE SENSITIVE
PTX PTX Presents at NobleCon12
21/01/16
PTX Response to ASX Price Query
19/01/16PRICE SENSITIVE
PTX Yale Hematolgy Leader Joins PTX Scientific Advisory Board
14/01/16
PTX PTX to present at Biotech Showcase 2016 in San Francisco
11/01/16
PTX FDA Allows PTX IND for Leukemia Phase Ib & II Trials
08/01/16PRICE SENSITIVE
PTX Appendix 3B - Release of securities from escrow
11/12/15
PTX Change of Director's Interest Notice
08/12/15
PTX Becoming a substantial holder
03/12/15
PTX Change in substantial holding
01/12/15
PTX Investor Presentation - December 2015
01/12/15
PTX Section 708A Cleansing Notice and Appendix 3B
30/11/15
PTX H. Lee Moffitt Cancer Center Leukaemia Oncologist Joins SAB
30/11/15
PTX MD Anderson Leukaemia Expert Joins PTX SAB
26/11/15
PTX Change in substantial holding
25/11/15
PTX Change of Director's Interest Notice x4
25/11/15
PTX Additional Placement Raises $1.0 million
25/11/15PRICE SENSITIVE
PTX Share Purchase Plan Completion & Appendix 3B
23/11/15
PTX Release of Securities from Escrow
20/11/15
PTX Share Purchase Plan Results
18/11/15
PTX PTX Shareholder Newsletter
09/11/15
PTX Results of Meeting
04/11/15
PTX New Investor Presentation
04/11/15
PTX Share Purchase Plan - Documentation issued to shareholders
02/11/15
PTX September 2015 Appendix 4C - Quarterly
30/10/15PRICE SENSITIVE
PTX Cleansing Notice - Share Purchase Plan
29/10/15
PTX Share Purchase Plan Offer Document
29/10/15
PTX SPP Fully Underwritten up to target amount of $1.03 million
29/10/15PRICE SENSITIVE
PTX Trading Halt
28/10/15PRICE SENSITIVE
PTX Final Director's Interest Notice
15/10/15
PTX Executive Management Change
15/10/15PRICE SENSITIVE
PTX Notice of Annual General Meeting/Proxy Form
05/10/15
PTX CSO named among Top 20 Translational Researchers by Nature
01/09/15
PTX Two new Patents granted to Protect Lead Asset PTX-200
31/08/15PRICE SENSITIVE
PTX 2015 Corporate Governance Statement and Appendix 4G
28/08/15
PTX Prescient Appendix 4E and 2015 Annual Report
28/08/15PRICE SENSITIVE
PTX PTX-200 Phase 1B/2 Clinical Trial Update
26/08/15PRICE SENSITIVE
PTX Proposed Grant of Options to Non-Executive Directors
21/08/15PRICE SENSITIVE
PTX Prescient Shareholder Newsletter
12/08/15
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
4.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $32.21M
Open High Low Value Volume
4.0¢ 4.1¢ 4.0¢ $22.35K 558.4K

Buyers (Bids)

No. Vol. Price($)
6 221774 3.9¢
 

Sellers (Offers)

Price($) Vol. No.
4.1¢ 860576 3
View Market Depth
Last trade - 14.51pm 19/11/2024 (20 minute delay) ?
Last
4.0¢ 		  Change
0.000 ( 1.27 %)
Open High Low Volume
4.0¢ 4.0¢ 4.0¢ 94998
Last updated 12.16pm 19/11/2024 ?
PTX (ASX) Chart

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Radiopharm extends radioimmunotherapy trial to 5 more cancer types Radiopharm Theranostics Ltd has received approval to extend its Phase 1 trial of Lu-RAD204 to five more cancer types
Things finally 'looking different' for up-and-down Hot Stock tip Stockland Wealth Within chief analyst Dale Gillham and senior analyst Fil Tortevski have named this week’s HotCopper Hot Stock tip: Real estate group Stockland (ASX:SGP).While Stockland has dipped up and down recently, Mr Tortevski conceded, things are @looking different&CloseCurlyDoubleQuo...
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.